Clinical Efficacy and Combination Therapy Development

Dr. Patel discusses clinical trial efficacy data from KOMET-001 evaluating ziftomenib safety and preliminary efficacy in R/R NPM1-mutated AML and AUGMENT-101 results for revumenib. Both studies demonstrate encouraging results with meaningful responses in heavily pretreated patients, particularly those previously receiving venetoclax. Many patients achieve excellent disease control enabling safe transplant progression, with manageable safety profiles providing excellent opportunities for NPM1-mutated relapsed disease management.

KOMET-001 demonstrated 23% to 25% complete remission rates with 35% overall response rates, whereas AUGMENT-101 showed 23% complete remission with count recovery rates and over 60% overall responses in heavily pretreated patients. Dr. Patel notes remarkably similar response rates across both studies, with median time to response of approximately 2 months requiring patient support through several therapy weeks before assessing drug effectiveness. Initial leukocytosis worsening may occur, emphasizing the importance of supporting patients through 6 to 8 weeks before determining therapeutic efficacy.

Caveats include duration of response typically lasting several weeks, particularly without allogeneic transplant consolidation after achieving remission. Median overall survival from therapy initiation ranges 4 to 5 months, indicating continued work needed in this space. However, achieving 25% remission rates in heavily pretreated patients, particularly as transplant bridges for eligible candidates, represents vital clinical practice incorporation considerations. Recent combination therapy presentations at ASH 2025 demonstrate improved responses, depth, and durability when combining menin inhibitors with other chemotherapy options, with KOMET-007 frontline setting responses reaching 80-90% with rapid responses and durable remissions.